Braeburn has resubmitted the New Drug Application for CAM2038 weekly and monthly formulations for opioid use disorder and if approved will be marketed in the U.S., under a licensing agreement with Camurus, in a range of dosage strengths for once weekly and once monthly subcutaneous injections.
Braeburn is also investigating CAM2038 in opioid tolerant patients with chronic pain as part of its ongoing pivotal Phase III program.
Learn more about the results of CAM2038’s clinical trials.
Braeburn is committed to supporting independent scientific research and independent medical education for the advancement of medical and scientific understanding in our therapeutic areas of interest.
Please note that Braeburn will not provide grant support for the following:
Note that no additional requests will be considered for 2018. Please check back again at a later date.